Bobby Neonatal
What is Apnea of Prematurity?
Apnea of Prematurity, or AoP, is a common condition affecting premature babies, and it involves pauses in their breathing that last for 15 to 20 seconds or even longer. During these episodes, it’s not uncommon for babies to experience a slowed heart rate, a condition known as bradycardia, as well as reduced oxygen levels in their blood, referred to as hypoxemia.
The primary cause of AoP lies in the immaturity of the brain’s respiratory control centers, which are not yet fully developed in premature infants. This can make it challenging for these babies to maintain regular breathing patterns on their own. As we discuss this condition, it’s important to consider the serious implications it can have on the health and development of these vulnerable babies.
Apnea of Prematurity, or AoP, is a common condition affecting premature babies, and it involves pauses in their breathing that last for 15 to 20 seconds or even longer. During these episodes, it’s not uncommon for babies to experience a slowed heart rate, a condition known as bradycardia, as well as reduced oxygen levels in their blood, referred to as hypoxemia.
The primary cause of AoP lies in the immaturity of the brain’s respiratory control centers, which are not yet fully developed in premature infants. This can make it challenging for these babies to maintain regular breathing patterns on their own. As we discuss this condition, it’s important to consider the serious implications it can have on the health and development of these vulnerable babies.
Our Mission
Bobby Neonatal provides automated skin stimulation to reduce Apnea of Prematurity, minimize nurse workload, and improve neonatal care
Our mission is to eliminate AoP in clinical settings while easing the alarm burden on nursing staff. Our vision is to revolutionize neonatal care by reducing the need for manual interventions, minimizing alarm fatigue, and improving outcomes for the 13.4 million premature babies born each year.
AoP affects 100% of infants born before 28 weeks and 70% of those born before 34 weeks, often leading to long-term cognitive and behavioral challenges. It is frequently accompanied by slowed heart rate and low oxygen levels, triggering multiple alarms per hour for each baby. This high alarm frequency contributes to alarm fatigue among nurses, potentially delaying responses and compromising care.
AoP affects 100% of infants born before 28 weeks and 70% of those born before 34 weeks, often leading to long-term cognitive and behavioral challenges. It is frequently accompanied by slowed heart rate and low oxygen levels, triggering multiple alarms per hour for each baby. This high alarm frequency contributes to alarm fatigue among nurses, potentially delaying responses and compromising care.
Our Technology
Addressing the challenge of AoP in premature babies
Bobby Neonatal’s innovative skin stimulation device mimics the skin-to-skin stimulation typically performed by nurses to end apnea in premature babies.
This automated solution delivers consistent and timely stimulation, reducing the risk of prolonged apnea episodes, supporting neurological development, and alleviating nurse workload by automating a repetitive task. By ensuring uniform care standards, Bobby Neonatal minimizes variability and human error, improving overall neonatal care.
This automated solution delivers consistent and timely stimulation, reducing the risk of prolonged apnea episodes, supporting neurological development, and alleviating nurse workload by automating a repetitive task. By ensuring uniform care standards, Bobby Neonatal minimizes variability and human error, improving overall neonatal care.
Company Status
Bobby Neonatal is transforming neonatal care nd tapping into a €1.25B market
Our automated skin stimulation solution aims to alleviate apnea in newborns, reduce nurse workload, and ensure consistent care delivery. With a total addressable market projected to reach €1.25 billion by 2035, the opportunity is substantial. Currently at the proof-of-concept stage, we have completed a 14-patient study at Leiden University Medical Center, demonstrating positive results—effectively ending apnea episodes and reducing time spent in lower oxygen-saturated states.
